Search Medical Condition
Please enter condition
Please choose location

Bilbao, Basurto Clinical Trials

A listing of Bilbao, Basurto clinical trials actively recruiting patients volunteers.

RESULTS

Found (40) clinical trials

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected ...

Phase

Safety Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis

The drug being tested in this study is called ixazomib. Ixazomib is being tested to find a safe and well tolerated dose in participants with lupus nephritis. This study will look at side effects and lab results in participants who take ixazomib, along with the determination of the pharmacokinetics (PK). ...

Phase

Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Phase

CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI

• Introduction: CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI) (www.center-tbi.eu) is a project embedded within the International Initiative on TBI Research (InTBIR) (http://intbir.nih.gov/), as a collaboration between the European Commission (EC), the US National Institute of Neurological Disorders and Stroke (NIH-NINDS) and the Canadian Institute of Health Research (CIHR). ...

Phase N/A

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified. These strokes are likely due to a blood clot and therefore, can be called embolic stroke of undetermined source. The abbreviation is ESUS. The study ...

Phase

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

This is a single-arm, multi-center, open-label extension study designed to provide pertuzumab to patients who continue to derive benefit from pertuzumab, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored Global study who continue ...

Phase

A Study of Cobimetinib in Combination With Paclitaxel Cobimetinib Plus Atezolizumab Plus Paclitaxel and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer

This three-cohort, multi-stage, randomized, Phase II, multicenter trial will evaluate the safety and tolerability and estimate the efficacy of cobimetinib plus paclitaxel versus placebo plus paclitaxel in Cohort I, of cobimetinib plus atezolizumab plus paclitaxel in Cohort II, and of cobimetinib plus atezolizumab plus nab-paclitaxel in Cohort III in participants ...

Phase

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to methotrexate monotherapy on maintenance of remission in subjects with Rheumatoid Arthritis who were on etanercept plus methotrexate therapy. This is a multicenter, randomized withdrawal, double-blind controlled study in subjects with Rheumatoid Arthritis on etanercept plus ...

Phase

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage) Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

This multicenter study uses a randomized, double-blind, placebo-controlled, parallel-group design. A screening period (SCR) running up to 10 weeks before randomization will be used to assess subject eligibility followed by 104 weeks of treatment. At BSL approximately 990 subjects whose eligibility is confirmed will be randomized to one of four ...

Phase

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

This is a prospective, observational, cohort study to collect data on adult participants who have a confirmed diagnosis of psoriatic arthritis (PsA) and are starting either STELARA or a new TNFi as a new therapy in a first, second, or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy. Approximately ...

Phase N/A